Quantitative Investment Management LLC Increases Position in The Cooper Companies, Inc. $COO

Quantitative Investment Management LLC increased its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 111.8% during the third quarter, Holdings Channel reports. The fund owned 36,024 shares of the medical device company’s stock after acquiring an additional 19,014 shares during the quarter. Quantitative Investment Management LLC’s holdings in Cooper Companies were worth $2,469,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of COO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Cooper Companies by 48.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock valued at $1,890,000 after acquiring an additional 7,363 shares during the last quarter. Campbell & CO Investment Adviser LLC boosted its holdings in shares of Cooper Companies by 29.8% during the second quarter. Campbell & CO Investment Adviser LLC now owns 12,487 shares of the medical device company’s stock worth $889,000 after purchasing an additional 2,866 shares during the last quarter. ProShare Advisors LLC grew its position in shares of Cooper Companies by 12.6% in the second quarter. ProShare Advisors LLC now owns 35,635 shares of the medical device company’s stock valued at $2,536,000 after purchasing an additional 3,990 shares during the period. Allworth Financial LP grew its position in shares of Cooper Companies by 36.6% in the second quarter. Allworth Financial LP now owns 959 shares of the medical device company’s stock valued at $68,000 after purchasing an additional 257 shares during the period. Finally, KBC Group NV increased its stake in Cooper Companies by 17.3% in the second quarter. KBC Group NV now owns 295,590 shares of the medical device company’s stock valued at $21,034,000 after purchasing an additional 43,622 shares during the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies Price Performance

COO stock opened at $71.52 on Friday. The stock has a 50-day moving average price of $81.45 and a two-hundred day moving average price of $75.97. The Cooper Companies, Inc. has a 12-month low of $61.78 and a 12-month high of $89.83. The company has a current ratio of 1.34, a quick ratio of 0.79 and a debt-to-equity ratio of 0.22. The company has a market cap of $13.95 billion, a PE ratio of 35.41, a price-to-earnings-growth ratio of 1.90 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, March 5th. The medical device company reported $1.10 EPS for the quarter, topping the consensus estimate of $1.03 by $0.07. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.02 billion. Cooper Companies had a return on equity of 10.34% and a net margin of 9.67%.The firm’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.92 earnings per share. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. As a group, research analysts predict that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Wall Street Analyst Weigh In

COO has been the topic of several recent analyst reports. Piper Sandler reiterated an “overweight” rating and set a $94.00 target price (up from $83.00) on shares of Cooper Companies in a research report on Friday, December 5th. Barclays upped their price objective on shares of Cooper Companies from $98.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, March 6th. Needham & Company LLC increased their price objective on shares of Cooper Companies from $99.00 to $101.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Mizuho set a $100.00 target price on shares of Cooper Companies and gave the stock an “outperform” rating in a research report on Friday, December 5th. Finally, Wall Street Zen upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $90.79.

Insider Buying and Selling at Cooper Companies

In other Cooper Companies news, Director Maria Rivas purchased 1,000 shares of Cooper Companies stock in a transaction on Thursday, December 18th. The shares were purchased at an average cost of $82.13 per share, with a total value of $82,130.00. Following the completion of the transaction, the director directly owned 11,141 shares in the company, valued at approximately $915,010.33. This represents a 9.86% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Holly R. Sheffield acquired 1,230 shares of the firm’s stock in a transaction on Tuesday, December 16th. The shares were acquired at an average price of $80.75 per share, with a total value of $99,322.50. Following the completion of the purchase, the insider owned 39,052 shares of the company’s stock, valued at $3,153,449. This trade represents a 3.25% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 16,014 shares of company stock worth $1,304,416. Company insiders own 2.08% of the company’s stock.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.